The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2
| Status: | Completed |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 3 - 4 |
| Updated: | 6/30/2018 |
| Start Date: | May 2010 |
| End Date: | May 2015 |
A preliminary study was conducted involving 88 three-year-old children with sickle cell
disease (SCD) who were followed at the St. Jude Children's Research Hospital Sickle Cell
Center. They were offered developmental screening with the Brigance Preschool Screen-II test
during their regular clinic visits from January 2006 to August 2008. Data from this work
showed that 50% of 3 year old children with SCD had low developmental screening scores. In
addition, the low scores were found to be associated with less parental education and with
speech deficits. However they were not associated with sickle cell genotype and hemoglobin
level.
The primary goal of this study is to prospectively administer Brigance Preschool Screen -II
to 3 year old children with SCD and 3 year old children without SCD who come from similar
socioeconomic backgrounds and compare the results between the two groups.
disease (SCD) who were followed at the St. Jude Children's Research Hospital Sickle Cell
Center. They were offered developmental screening with the Brigance Preschool Screen-II test
during their regular clinic visits from January 2006 to August 2008. Data from this work
showed that 50% of 3 year old children with SCD had low developmental screening scores. In
addition, the low scores were found to be associated with less parental education and with
speech deficits. However they were not associated with sickle cell genotype and hemoglobin
level.
The primary goal of this study is to prospectively administer Brigance Preschool Screen -II
to 3 year old children with SCD and 3 year old children without SCD who come from similar
socioeconomic backgrounds and compare the results between the two groups.
The primary objective of this study is to compare development in 3 year old children with SCD
who are not on any treatment to age matched healthy controls using pass/fail rate for the
Brigance Preschool Screen II.
Secondary objectives:
1. To compare the raw scores of the Brigance Preschool Screen II between SCD and control
groups.
2. To compare the pass/fail rate and the raw scores between SCD patients who are not on any
treatment and those who are being treated with hydroxyurea.
3. To compare the pass/fail rate and the raw scores between SCD patients on hydroxyurea
treatment and the healthy controls
4. To assess the influence of medical factors on the Brigance Preschool Screen II
performance in children with SCD.
5. To assess the influence of socioeconomic factors on the Brigance Preschool II results in
children with SCD and controls.
who are not on any treatment to age matched healthy controls using pass/fail rate for the
Brigance Preschool Screen II.
Secondary objectives:
1. To compare the raw scores of the Brigance Preschool Screen II between SCD and control
groups.
2. To compare the pass/fail rate and the raw scores between SCD patients who are not on any
treatment and those who are being treated with hydroxyurea.
3. To compare the pass/fail rate and the raw scores between SCD patients on hydroxyurea
treatment and the healthy controls
4. To assess the influence of medical factors on the Brigance Preschool Screen II
performance in children with SCD.
5. To assess the influence of socioeconomic factors on the Brigance Preschool II results in
children with SCD and controls.
PATIENT GROUP
Inclusion criteria:
- 3.0-<4.0 years of age
- African-American
- Diagnosis of sickle cell disease (HbSS, HbSC, HbSβºthalassemia, HbSβ^+thalassemia)
- Followed at St. Jude Children's Research Hospital Sickle Cell Center
Exclusion criteria:
- Previous stroke
- Patients who are currently on a chronic transfusion program
- Known diagnosis associated with significant cognitive impairment (e.g. Down syndrome,
mental retardation)
- Previously tested with Brigance Preschool Screen-II
CONTROL GROUP
Inclusion criteria:
- 3.0-<4.0 years of age
- African-American
- Attendee of day-care in Memphis area
Exclusion criteria:
1. Known diagnosis associated with significant cognitive impairment (e.g. stroke, Down
syndrome, mental retardation)
2. Known diagnosis sickle cell disease (HbSS, HbSC, HbSβºthalassemia, HbSβ^+thalassemia)
3. Previously tested with Brigance Preschool Screen-II
We found this trial at
1
site
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
